Journal
CANCER SCIENCE
Volume 107, Issue 7, Pages 1013-1017Publisher
WILEY-BLACKWELL
DOI: 10.1111/cas.12951
Keywords
The Era of molecular targeted therapy; interferon-alpha; overall survival; prognostic factors; renal cell carcinoma
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology, Japan [16390466]
- Grants-in-Aid for Scientific Research [16390466] Funding Source: KAKEN
Ask authors/readers for more resources
The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-alpha (IFN-alpha). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan-Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-alpha using large cohort of the prospective study. The present study suggests that first-line IFN-alpha is still a useful therapy for mRCC even in the era of molecular targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available